MyBioSource

antibody

Insulin antibody

MBS531424

1 mg

545 USD

monoclonal

mouse

human

ELISA, enzyme immunoassay

MBS531424

Antibody

Insulin antibody

Insulin

Monoclonal Insulin; Anti-Insulin

insulin; Insulin; insulin; proinsulin; preproinsulin; insulin; N/A

INS; INS; ILPR; IRDN; IDDM2; MODY10; N/A

INS_HUMAN

Monoclonal

IgG1

E6E5

Mouse

Specific to human insulin. Cross react with human proinsulin, bovine insuline (30%), and porcine insuline. No cross-reaction with free C-peptide.

Human

Insulin antibody was purified by chromatography on protein A Sepharose.

Liquid in PBS buffer containing 0.1 % sodium azide, pH 7.4.

10.7mg/ml

Store at 4 deg C or -20 deg C for longer storage.

ELISA (EIA)

Immunogen: Purified human insulin. Affinity Constant: ~7.5 x 10^9 Liters/Mole

Biohazard Information: This product contains sodium azide as preservative. Although the amount of sodium azide is very small appropriate care must be taken when handling this product. Additional Remarks: Detection of insulin in two-site enzyme immunoassay.

Hormones & Steroids; Monoclonal Antibodies

Mouse monoclonal Insulin antibody. Insulin causes the cells in the liver, muscle, and fat tissue to take up glucose from blood and convert it to glycogen that can be stored in the liver and muscles. Insulin also prevents the utilization of fat as an energy source. In absence of insulin or in conditions where insulin is low glucose is not taken up by body cells, and the body begins to use fat as an energy source

386828

AAA59172.1

P01308

11,981 Da

ATF-2 Transcription Factor Network Pathway 138006!!Adipogenesis Pathway 198832!!Aldosterone-regulated Sodium Reabsorption Pathway 130626!!Aldosterone-regulated Sodium Reabsorption Pathway 130590!!Amyloids Pathway 366238!!Arf6 Trafficking Events Pathway 137954!!Developmental Biology Pathway 477129!!Diabetes Pathways 105902!!Disease Pathway 530764!!FOXA1 Transcription Factor Network Pathway 137979

After removal of the precursor signal peptide, proinsulin is post-translationally cleaved into three peptides: the B chain and A chain peptides, which are covalently linked via two disulfide bonds to form insulin, and C-peptide. Binding of insulin to the insulin receptor (INSR) stimulates glucose uptake. A multitude of mutant alleles with phenotypic effects have been identified. There is a read-through gene, INS-IGF2, which overlaps with this gene at the 5' region and with the IGF2 gene at the 3' region. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2010]

Function: Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. Subunit structure: Heterodimer of a B chain and an A chain linked by two disulfide bonds. Subcellular location: Secreted. Involvement in disease: Defects in INS are the cause of familial hyperproinsulinemia (FHPRI) [. MIM:176730]. Ref.21 Ref.23 Ref.24 Ref.25Defects in INS are a cause of diabetes mellitus insulin-dependent type 2 (IDDM2) [. MIM:125852]. IDDM2 is a multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Ref.34Defects in INS are a cause of diabetes mellitus permanent neonatal (PNDM) [. MIM:606176]. PNDM is a rare form of diabetes distinct from childhood-onset autoimmune diabetes mellitus type 1. It is characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Permanent neonatal diabetes requires lifelong therapy. Ref.32 Ref.33Defects in INS are a cause of maturity-onset diabetes of the young type 10 (MODY10) [. MIM:613370]. MODY10 is a form of diabetes that is characterized by an autosomal dominant mode of inheritance, onset in childhood or early adulthood (usually before 25 years of age), a primary defect in insulin secretion and frequent insulin-independence at the beginning of the disease. Ref.33 Ref.34 Ref.35. Pharmaceutical use: Available under the names Humulin or Humalog (Eli Lilly) and Novolin (Novo Nordisk). Used in the treatment of diabetes. Humalog is an insulin analog with 52-Lys-Pro-53 instead of 52-Pro-Lys-53. Sequence similarities: Belongs to the insulin family. Sequence caution: The sequence AAA59179.1 differs from that shown. Reason: Erroneous gene model prediction.

1 mg

545 USD